Decreased blood levels of B lymphocytes and NK cells in patients with systemic lupus erythematosus (SLE) infected with papillomavirus (HPV)

Archives of Dermatological Research

Volumn 305, Issue 2, 2013, Pages 117-123

  Abud Mendoza, C ^a   Cuevas Orta, E ^a   Santillan Guerrero E N ^a   Martinez Martinez M U ^a   Hernandez Castro B ^a   Estrada Capetillo, L ^a   Gonzalez Amaro R ^a   Baranda, L ^a  

^a UNIVERSIDAD AUTÓNOMA DE SAN LUIS POTOSÍ   (Mexico)

Author keywords

B lymphocytes; Human papillomavirus; Immunosuppressive drugs; NK cells; Systemic lupus erythematosus

Indexed keywords

AZATHIOPRINE; CD16 ANTIBODY; CD19 ANTIBODY; CD20 ANTIBODY; CD22 ANTIBODY; CD3 ANTIBODY; CD335 ANTIBODY; CD4 ANTIBODY; CD56 ANTIBODY; CD8 ANTIBODY; HYDROXYCHLOROQUINE; IMMUNOSUPPRESSIVE AGENT; METHOTREXATE; MONOCLONAL ANTIBODY; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NATURAL CYTOTOXICITY TRIGGERING RECEPTOR 1; PREDNISONE; SIMVASTATIN; UNCLASSIFIED DRUG;

ADULT; ARTICLE; B LYMPHOCYTE; BLOOD ANALYSIS; CELL LOSS; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CONTROLLED STUDY; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG EFFECT; FEMALE; FLOW CYTOMETRY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION RISK; LOW DRUG DOSE; LYMPHOCYTE SUBPOPULATION; MALE; NATURAL KILLER CELL; PAPILLOMAVIRUS INFECTION; PRIORITY JOURNAL; RISK ASSESSMENT; SYSTEMIC LUPUS ERYTHEMATOSUS; VIRAL SKIN DISEASE;

ADULT; B-LYMPHOCYTES; BLOOD CIRCULATION; FEMALE; HUMANS; IMMUNITY, CELLULAR; IMMUNOSUPPRESSIVE AGENTS; KILLER CELLS, NATURAL; LUPUS ERYTHEMATOSUS, SYSTEMIC; LYMPHOCYTE COUNT; MALE; MIDDLE AGED; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; YOUNG ADULT;

EID: 84878853078     PISSN: 03403696     EISSN: 1432069X     Source Type: Journal    
DOI: 10.1007/s00403-012-1258-9     Document Type: Article

References (28)

1. Arens MJ, Wyllie AH, Bird CC (1990) Papillomaviruses and human cancer. Hum Pathol 21:686-698
2. Barzegar C, Paul C, Saiag P, Cassenot P, Bachelez H, Autran B, Gorochov G, Petit A, Dubertret L (1998) Epidermodysplasia verruciformis-like eruption complicating human immunodeficiency virus infection. Br J Dermatol 139:122-127
3. Blumenfeld Z, Lorber M, Yofee N, Scharf Y (1994) Systemic lupus erythematosus: predisposition for uterine cervical dysplasia. Lupus 3:59-61
4. Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH (1992) Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis studies in SLE. Arthr Rheum 35:630-640
5. Bonagura VR, Hatam LJ, Rosenthal DW, de Voti JA, Lam F, Steinberg BM, Abramson AL (2010) Recurrent respiratory papillomatosis: a complex defect in immune responsiveness to human papillomavirus-6 and 11. APMIS 118:455-470
6. Cutts FT, Franceschi S, Goldie S, Castellsague X, de Sanjose S, Garnett G, Edmunds WJ, Claeys P, Goldenthal KL, Harper DM, Markowitz L (2007) Human papillomavirus and HPV vaccines: a review. Bull World Health Org 85:719-726
7. Cluffo G (1907) Innesto positive confiltrato di verruca volgare (positive verruca vulgaris inoculatium using a filtered inoculum). G Ital Mal Venereol 48:12-17
8. Dave R, Monk B, Mahaffey P (2002) Spontaneous disappearance of refractory viral warts at distant sites following carbon-dioxide laser treatment. Br J Plast Surg 55:696-698
9. Davey DD (2003) Cervical cytology classification and the Bethesda System. Cancer J 9:327-334
10. De Roy PG (2004) Helsinki and the Declaration of Helsinki. World Med J 50:9-11
11. Febronio MV, Pereira RM, Bonfa E, Takiuti AD, Pereyra EA, Silva CA (2007) Inflammatory cervicovaginal cytology is associated with disease activity in juvenile systemic lupus erythematosus. Lupus 16:430-435
12. Firnhaber C, Van Le H, Pettifor A, Schulze D, Michelow P, Sanne IM, Lewis DA, Williamson AL, Allan B, Williams S, Rinas A, Levin S, Smith JS (2010) Association between cervical dysplasia and human papillomavirus in HIV seropositive women from Johannesburg South Africa. Cancer Causes Control 21:433-443
13. Garzetti GG, Ciavattini A, Goteri G, Nictolis M, Menso S, Muzzioli M, Fabris N (1995) HPV DNA positivity and natural killer activity in the clinical outcome of mild cervical dysplasia: integration between virus and immune system. Gynecol Obstet Invest 39:130-135
14. Johansson E, Pyrhönen S, Rostila T (1977) Warts and wart virus in patients with systemic lupus erythematosus. Br Med J 1:74-76
15. Klumb EM, Pinto AC, Jesus GR, Araujo M Jr, Jascone L, Gayer CR, Ribeiro FM, Albuquerque EM, Macedo JM (2010) Are women with lupus at higher risk of HPV infection? Lupus 19:1485-1491
16. Korkmaz C, Ürer SM (2004) Cutaneous warts in patients with lupus erythematosus. Rheumatol Int 24:137-140
17. Kostaki M, Venetz JP, Nseir G, Meylan P, Sahli R, Pascual M, Laffitte E (2010) Giant warts in a kidney transplant patient: regression with sirolimus. Br J Dermatol 162:1148-1150
18. Kuijpers TW, Baars PA, Dantin C, van den Burg M, van Lier RA, Roosnek E (2008) Human NK cells can control CMV infection in the absence of T cells. Blood 112:914-915
19. Maeda K, Jimbow K, Fukushima M, Sawada Y, Fujinaga K (1985) Epidermodysplasia verruciformis associated with Bowen's carcinoma, B lymphocytopenia and decreased immune functions. Dermatologica 171:478-485
20. Matteucci P, Magni M, Di Nicola M, Carlo-Stella C, Uberti C, Gianni AM (2002) Leukoencephalopathy and papovavirus infection after treatment with chemotherapy and anti-CD20 monoclonal antibody. Blood 100:1104-1105
21. Nebesio CL, Mirowsky GW, Chuang T (2001) Human papillomavirus: clinical significance and malignant potential. Int J Dermatol 40:373-379
22. Ohata K, Espinoza JL, Lu X, Kondo Y, Nakao S (2011) Mycophenolic acid inhibits natural killer proliferation and cytotoxic function: a possible disadvantage of including mycophenolate mofetil in the graft-versus-host disease prophylaxis regimen. Biol Blood Marrow Transplant 17:205-213
23. Ritter ML, Pirofski L (2009) Mycophenolate mofetil: effects on cellular immune subsets, infectious complications, and antimicrobial activity. Transpl Infect Dis 11:290-297
24. Santana IU, Gomes Ado N, Lyrio LD, Rios Grassi MF, Santiago MB (2011) Systemic lupus erythematosus, human papillomavirus infection, cervical pre-malignant and malignant lesions: a systematic review. Clin Rheumatol 30:665-672
25. Schiffman MH, Bauer HM, Hoover RN (1993) Epidemiologic evidence showing that human papillomavirus infection causes most cervical intraepithelial neoplasia. J Natl Cancer Inst 85:958-964
26. Schmook T, Nindl I, Ulrich C, Meyer T, Sterry W, Stockfleth E (2003) Viral warts in organ transplant recipients: new aspects in therapy. Br J Dermatol 149(Suppl 66):20-24
27. Scott M, Nakagawa M, Moscicki AB (2001) Cell-mediated immune response to human papillomavirus infection. Clin Diagn Lab Immunol 8:209-220
28. Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, Schaller JG, Talal N, Winchester RJ (1982) The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 25:1271-1277